Given the lack of high-quality evidence, the role of GnRH antagonists in the luteal phase for the prevention of OHSS is uncertain, and they should not be used as an isolated strategy to prevent moderate-to-severe OHSS. Here, GNRH1 is linked to ovarian hyperstimulation syndrome.